There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCVpositive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) whofailed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%)
Retrospective, observational multicenter study on an italian population affectred by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and Ribavirin): NADIR study / F. Morisco; T. Stroffolini; E. Medda; DC. Amoruso ; PL. Almasio; E. Villa; M. Zuin; B. Paris; M. Stanzione ; N. Caporaso; NADIR study group; Aceti A; ..; A.L. Zignego.. - In: JOURNAL OF VIRAL HEPATITIS. - ISSN 1352-0504. - STAMPA. - 17(6):(2010), pp. 427-434.
Retrospective, observational multicenter study on an italian population affectred by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and Ribavirin): NADIR study
ZIGNEGO, ANNA LINDA
2010
Abstract
There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCVpositive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) whofailed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%)File | Dimensione | Formato | |
---|---|---|---|
2010 Morisco J Vir Hepatitis.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
90.56 kB
Formato
Adobe PDF
|
90.56 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.